Approximating the Baseline Hazard Function by Taylor Series for Interval-Censored Time-to-Event Data

By Chen Ding-Geng  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 3, 2013-05 ,pp. : 695-708

Taylor & Francis Ltd

Access to resources Recommend Favorite

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas   Eichelberg Christian   Sun Maxine  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite

Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Halabi Susan   Rini Brian I.   Escudier Bernard   Stadler Walter M.   Small Eric J.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1906

Blackwell Publishing

Access to resources Recommend Favorite

Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

By Rothmann Mark   Koti Kallappa   Lee Kyung Yul   Lu Hong Laura   Shen Yuan Li   Zhang Jenny J.   Jin Mei   Zhou Haojin  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1091-1105

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Ratio Test in Active Control Non-Inferiority Trials with a Time-to-Event Endpoint

By Wang Yong-Cheng  

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 2, 2006-03 ,pp. : 151-164

Taylor & Francis Ltd

Access to resources Recommend Favorite